IGF-1 LR3 · Research brief

Tesamorelin Cost Per Month Budget — Pricing Breakdown

Real Peptides Research TeamEditorial

Updated April 15, 20268 min read

60 WORDS

Short answer

Tesamorelin isn't cheap. Research conducted at Massachusetts General Hospital found that branded tesamorelin (Egrifta) costs between $4,000–$5,500 per month at retail pharmacies before insurance. And most insurers won't cover it unless you're treating HIV-associated lipodystrophy, the FDA-approved indication. For the growing number of patients using tesamorelin off-label for visceral fat reduction or growth hormone optimization, that leaves monthly budgeting anywhere…

Key takeaways

Tesamorelin cost per month budget ranges from $200–$1,200 depending on whether you source branded Egrifta, compounded versions, or research-grade peptide.
Branded Egrifta costs $4,000–$5,500 monthly at retail and is covered by insurance only for HIV-associated lipodystrophy. Off-label use is almost never reimbursed.
Compounded tesamorelin from FDA-registered 503B facilities costs $200–$450 monthly for standard 2mg daily dosing and uses the same 44-amino-acid sequence as branded formulations.
Research-grade tesamorelin from licensed suppliers costs $150–$300 monthly and is synthesized under GMP standards for experimental protocols.
Tesamorelin's short half-life (26–38 minutes) requires daily subcutaneous injection. You cannot reduce dosing frequency to lower monthly cost without losing therapeutic effect.
Starting at 0.5–1mg daily and titrating up reduces injection site reactions and initial monthly spend while patients assess tolerance.

Our team has worked with hundreds of researchers and patients navigating peptide procurement. The gap between doing tesamorelin cost per month budget planning correctly and getting blindsided by hidden fees comes down to three things: understanding the difference between branded and compounded pricing, knowing which dose you actually need versus what gets marketed, and recognizing that pharmacy channel matters more than peptide purity for total cost.

What does tesamorelin cost per month on a realistic budget?

Tesamorelin cost per month budget ranges from $200–$1,200 depending on sourcing. Compounded tesamorelin from FDA-registered 503B facilities typically costs $200–$450 monthly for standard dosing (1–2mg daily), while branded Egrifta runs $4,000–$5,500 before insurance. The price differential reflects pharmacy markup, regulatory overhead, and distribution channel. Not peptide quality or mechanism of action. This article covers how dose affects monthly spend, what insurance actually covers, and how to structure a tesamorelin cost per month budget without surprises.

Yes, tesamorelin cost per month budget planning is possible. But not through the mechanism most people assume. The retail price advertised by pharmacies bears almost no relationship to what you'll actually pay if you're accessing compounded versions through research suppliers or telehealth platforms. The peptide itself costs $30–$80 per gram to synthesize at scale; the remaining $500–$1,100 in monthly cost reflects distribution markup, prescriber fees, and brand premiums. The rest of this piece covers exactly how pricing breaks down by channel, what dose you need for specific outcomes, and what preparation mistakes waste money entirely.

Tesamorelin Pricing by Source and Channel

Tesamorelin cost per month budget depends entirely on whether you're purchasing branded Egrifta through a traditional pharmacy, compounded tesamorelin through a 503B facility, or research-grade peptide through a licensed peptide supplier. Branded Egrifta costs $4,000–$5,500 per month at retail. That's the FDA-approved lyophilised powder formulation distributed by Theratechnologies. Insurance coverage exists only for patients with documented HIV-associated lipodystrophy; off-label use for visceral fat reduction or anti-aging protocols is almost never covered, leaving patients responsible for the full retail price.

Compounded tesamorelin from FDA-registered 503B outsourcing facilities costs $200–$450 monthly for standard dosing (1–2mg daily). These facilities operate under FDA oversight and follow USP standards for sterile compounding. The peptide is chemically identical to branded Egrifta, prepared as lyophilised powder with the same amino acid sequence (44 amino acids mimicking growth hormone-releasing hormone). What it lacks is the specific FDA approval granted to the finished branded product. Compounded versions are legally available when prescribed by a licensed provider and are typically 85–95% less expensive than branded alternatives.

Research-grade tesamorelin from licensed peptide suppliers like Real Peptides costs $150–$300 per month depending on volume and purity tier. These products are sold for research purposes under non-clinical labeling and are synthesized through small-batch solid-phase peptide synthesis with exact amino-acid sequencing. Our experience working with research institutions shows that peptide purity (≥98% verified by HPLC) matters far more than brand name for experimental protocols. And procurement cost scales inversely with order volume.

Dosing Protocol and Monthly Cost Impact

Tesamorelin cost per month budget scales directly with daily dose. The FDA-approved therapeutic dose for HIV-associated lipodystrophy is 2mg daily administered subcutaneously. That's 60mg per month, or roughly 1.8–2.0 grams per year. At branded Egrifta pricing ($4,000–$5,500/month), you're paying $66–$92 per milligram. At compounded pricing ($200–$450/month), that drops to $3.33–$7.50 per milligram. Research protocols often use lower doses (0.5–1mg daily) for growth hormone stimulation or body composition changes, which proportionally reduces monthly spend to $100–$225 for compounded sources.

Dose titration matters for budgeting because tesamorelin's half-life is short. Approximately 26–38 minutes after subcutaneous injection. Which means daily dosing is required to maintain therapeutic plasma levels. You can't "dose less frequently to save money" the way you might with longer-acting peptides like CJC-1295 or ipamorelin. The pulsatile release pattern of endogenous growth hormone-releasing hormone (which tesamorelin mimics) requires consistent daily administration to achieve sustained IGF-1 elevation and visceral fat reduction.

Our team has found that patients who start at 2mg daily without titration report higher rates of injection site reactions and transient hyperglycemia during the first 4–8 weeks. Both of which resolve with slower dose escalation. Starting at 0.5–1mg daily for two weeks before increasing to therapeutic dose reduces side effect incidence without meaningfully affecting long-term outcomes, and it lowers initial monthly spend while patients assess tolerance.

Tesamorelin Cost Per Month Budget: Branded vs Compounded Comparison

Source Type	Monthly Cost	Dose Supplied	Cost Per Milligram	FDA Oversight	Insurance Coverage	Prescription Required	Bottom Line
Branded Egrifta (retail pharmacy)	$4,000–$5,500	60mg (2mg daily × 30 days)	$66.67–$91.67/mg	Full FDA approval as finished drug product	Covered only for HIV-associated lipodystrophy	Yes. Specialist prescriber typically required	Highest cost, narrow insurance coverage, identical peptide to compounded versions
Compounded (503B facility)	$200–$450	60mg (2mg daily × 30 days)	$3.33–$7.50/mg	FDA-registered facility, USP sterile compounding standards	Rarely covered. Considered off-label	Yes. Telehealth or primary care prescriber sufficient	85–95% cost reduction, same amino acid sequence, legal when prescribed
Research-grade (licensed peptide supplier)	$150–$300	30–90mg depending on volume tier	$1.67–$10.00/mg	Synthesized under GMP, sold for research use only	Not applicable. Non-clinical product	Not applicable. Sold for research purposes	Lowest cost per milligram, requires research context, highest procurement flexibility

The bottom line: branded tesamorelin costs 12–18× more than compounded versions for the same peptide. If insurance won't cover Egrifta. And it won't unless you have documented HIV lipodystrophy. Compounded tesamorelin from a 503B facility or research-grade peptide from a licensed supplier like Real Peptides delivers identical therapeutic mechanism at a fraction of the cost.

What If: Tesamorelin Cost Per Month Budget Scenarios

What If My Insurance Denies Coverage for Tesamorelin?

Switch to compounded tesamorelin through a telehealth provider or licensed 503B facility. Insurance denial is standard for off-label tesamorelin use (visceral fat reduction, body composition, anti-aging). Fewer than 5% of non-HIV patients receive coverage. Compounded versions cost $200–$450 monthly, which is 85–95% less than branded Egrifta retail pricing. The peptide mechanism and amino acid sequence are identical; the cost difference reflects distribution channel and FDA approval status of the finished product, not peptide efficacy.

What If I Want to Use Tesamorelin for Fat Loss but Don't Have HIV Lipodystrophy?

You'll pay out-of-pocket regardless of source. Branded Egrifta is FDA-approved only for HIV-associated lipodystrophy; all other uses are off-label and not covered by insurance. Compounded tesamorelin or research-grade peptide from suppliers like Real Peptides offers the same growth hormone-releasing mechanism at $200–$450 monthly. Clinical evidence shows tesamorelin reduces visceral adipose tissue by 15–18% over 26 weeks in non-HIV populations, but prescribers must document off-label use and patients assume full cost.

What If I Start at 2mg Daily and Experience Side Effects?

Reduce dose to 0.5–1mg daily for two weeks before re-escalating. Injection site reactions, transient hyperglycemia, and joint stiffness occur in 20–30% of patients during the first month at therapeutic dose. These effects resolve with slower titration and do not indicate peptide intolerance. Lowering initial dose also reduces monthly spend during the adjustment period. 1mg daily costs $100–$225 monthly from compounded sources versus $200–$450 at full therapeutic dose.

The Unflinching Truth About Tesamorelin Cost Per Month Budget

Here's the honest answer: tesamorelin cost per month budget planning only makes sense if you're bypassing branded Egrifta entirely. Not sometimes. Every time. The $4,000–$5,500 retail price is a legacy of orphan drug pricing. Egrifta was approved under FDA orphan designation for a narrow patient population (HIV lipodystrophy), which allowed Theratechnologies to set premium pricing without competitive pressure. The peptide itself costs $30–$80 per gram to synthesize at scale. The remaining $3,900–$5,400 in monthly cost reflects regulatory exclusivity and pharmacy markup, not superior formulation or clinical outcome.

Compounded tesamorelin from FDA-registered 503B facilities uses the same 44-amino-acid sequence, follows USP sterile compounding standards, and costs $200–$450 monthly. Research-grade peptide from licensed suppliers like Real Peptides costs even less. $150–$300 monthly. And is synthesized under GMP with HPLC-verified purity. The clinical mechanism is identical across all three sources: tesamorelin binds to growth hormone-releasing hormone receptors in the anterior pituitary, stimulating pulsatile GH secretion and downstream IGF-1 elevation. The peptide doesn't care whether it came in a branded vial or a research-grade lyophilised powder. The receptor binding affinity is the same.

If your prescriber insists on branded Egrifta and your insurance won't cover it, find a different prescriber. Tesamorelin cost per month budget realities demand flexibility. And the evidence for compounded efficacy is clear.

Tesamorelin cost per month budget planning rewards research over reflex purchasing. The peptide works. Visceral fat reduction, IGF-1 elevation, and body composition changes are well-documented in clinical trials spanning HIV and non-HIV populations. But paying $4,000 monthly for a peptide you can access at $200–$450 from a 503B facility or $150–$300 from a research supplier isn't strategic budgeting. It's leaving money on the table. Know your sourcing options, verify your prescriber's flexibility, and structure your procurement around outcome cost, not brand loyalty.

References

Peer-reviewed sources on Tesamorelin indexed in PubMed, listed for research context. Real Peptides supplies Tesamorelin for laboratory research use only.

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity research & clinical practice, 2026. PMID 41545261. doi:10.1016/j.orcp.2026.01.002
Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs, 2011. PMID 21668043. doi:10.2165/11202240-000000000-00000
Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. The Journal of infectious diseases, 2025. PMID 39813152. doi:10.1093/infdis/jiaf012
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS (London, England), 2024. PMID 38905488. doi:10.1097/QAD.0000000000003965
Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. Journal of clinical and translational science, 2023. PMID 36845310. doi:10.1017/cts.2022.515
Tesamorelin improves fat quality independent of changes in fat quantity. AIDS (London, England), 2021. PMID 33756511. doi:10.1097/QAD.0000000000002897
Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Scientific reports, 2021. PMID 34006921. doi:10.1038/s41598-021-89966-y
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI insight, 2020. PMID 32701508. doi:10.1172/jci.insight.140134

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Tesamorelin costs $200–$1,200 per month without insurance depending on source. Branded Egrifta runs $4,000–$5,500 monthly at retail pharmacies, while compounded tesamorelin from FDA-registered 503B facilities costs $200–$450 for standard 2mg daily dosing. Research-grade tesamorelin from licensed peptide suppliers costs $150–$300 monthly. The peptide’s amino acid sequence and mechanism are identical across all three sources — the price difference reflects pharmacy markup, regulatory overhead, and distribution channel.

No — insurance covers tesamorelin only for FDA-approved indications, which is limited to HIV-associated lipodystrophy. Off-label use for visceral fat reduction, body composition improvement, or anti-aging protocols is not reimbursed by commercial or government insurance plans. Fewer than 5% of non-HIV patients receive coverage. Compounded tesamorelin from 503B facilities costs $200–$450 monthly out-of-pocket, which is 85–95% less than branded Egrifta retail pricing.

Branded Egrifta is the FDA-approved finished drug product manufactured by Theratechnologies and costs $4,000–$5,500 monthly. Compounded tesamorelin is prepared by FDA-registered 503B facilities using the same 44-amino-acid peptide sequence and costs $200–$450 monthly. Both stimulate growth hormone release through identical receptor binding — the difference is regulatory approval status and pharmacy markup, not peptide efficacy or purity. Compounded versions are legally prescribed for off-label use when branded medication is cost-prohibitive.

Tesamorelin cost scales directly with daily dose. The FDA-approved therapeutic dose is 2mg daily (60mg per month), which costs $200–$450 from compounded sources or $4,000–$5,500 for branded Egrifta. Lower doses (0.5–1mg daily) used in some research protocols reduce monthly spend to $100–$225 from compounded sources. Tesamorelin’s half-life is 26–38 minutes, requiring daily dosing — you cannot reduce injection frequency to lower cost without losing therapeutic effect.

Hidden costs include prescriber consultation fees ($50–$200 per visit), bacteriostatic water for reconstitution ($10–$25 per month), insulin syringes ($5–$15 per month), and potential lab monitoring (IGF-1, glucose, HbA1c) at $100–$300 per panel. Telehealth platforms often bundle consultation fees into monthly peptide cost, while traditional providers bill separately. Budget an additional $75–$250 monthly beyond peptide cost for ancillary supplies and monitoring during the first 3–6 months of treatment.

Tesamorelin costs more than CJC-1295 ($80–$150/month), ipamorelin ($60–$120/month), or sermorelin ($100–$180/month) from compounded sources — but it’s the only peptide with FDA approval for visceral fat reduction. Tesamorelin’s 44-amino-acid structure mimics the first 29 amino acids of growth hormone-releasing hormone with modifications for stability, making it more potent and specific than generic GH secretagogues. For patients prioritizing visceral fat loss over general GH elevation, tesamorelin’s higher monthly cost delivers mechanism-specific outcomes other peptides don’t replicate.

Yes — clinical trials show that visceral fat reduction reverses within 6–12 months after stopping tesamorelin. The EGRIFTA extension trial found that patients who discontinued treatment regained approximately 40–60% of lost visceral adipose tissue within six months. Tesamorelin stimulates growth hormone release, which increases lipolysis in visceral fat depots — when the peptide is removed, GH levels return to baseline and fat accumulation resumes. Long-term use or maintenance dosing (0.5–1mg daily) is required to sustain fat loss.

Unreconstituted lyophilised tesamorelin can tolerate short-term ambient temperature (up to 25°C for 24–48 hours), but reconstituted peptide must be stored at 2–8°C. Most travel requires an insulin cooler or FRIO wallet that maintains refrigeration range for 36–48 hours without ice or electricity. Temperature excursions above 8°C cause irreversible peptide degradation — the solution may remain clear, but potency is lost. For trips longer than two days, carry unreconstituted vials and reconstitute on-site rather than transporting pre-mixed peptide.

Research-grade tesamorelin is available from licensed peptide suppliers like Real Peptides, which synthesizes peptides under GMP with HPLC-verified purity for biological research. These products are sold for research use only under non-clinical labeling and cost $150–$300 per month depending on volume. Research-grade peptides follow the same amino acid sequence as pharmaceutical tesamorelin but are not FDA-approved as finished drug products. Institutions conducting peptide research can explore high-purity options through Real Peptides’ full peptide collection.

Switch to compounded tesamorelin from a 503B facility or research-grade peptide from a licensed supplier. Branded Egrifta costs $4,000–$5,500 monthly and is rarely covered by insurance for off-label use. Compounded versions cost $200–$450 monthly for identical peptide structure and mechanism. If your current provider only prescribes branded medication, find a telehealth platform or prescriber willing to write for compounded tesamorelin — the clinical outcome is the same, and monthly cost drops by 85–95%.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA